“Women are not dying because of diseases we cannot treat. They are dying because societies have yet to make the decision that their lives are worth saving.”
Prof. Mahmoud Fathalla,MD, PhD, 1997
Former President of the International Federation of Gynaecology and Obstetrics
Professor of Obstetrics and Gynaecology, Assiut University, Egypt.
Recommended DosesRecommended doses of Misoprostol (Cytotec®) are provided in this site along with instructions for use. Misoprostol is an E1 prostaglandin analogue which has been approved in more than 85 countries since its first marketing in 1985. So far it is approved only for the treatment of gastric ulcer (although France, Brazil, Taiwan and Egypt have licensed dedicated products for gynaecological or obstetrical use). This is remarkable given the abundant literature supporting its safety and effectiveness for multiple reproductive health indications. In some of these situations, misoprostol may be life-saving. The current patent holder has never applied to get a licence for Cytotec® for any of these indications. Consequently it is used off label in most countries and without package inserts to inform users about safe dosages. This site has been set up to distribute dosage guidelines for the use of misoprostol in obstetrics and gynaecology. The correct dosage varies greatly according to gestation, indication and route of administration - using the correct dosage is vital for success and to prevent complications. A summary is shown below. An extensive bibliography of over 1500 misoprostol references (produced July 2007) is also available. And evidence that misoprostol availability reduces mortality and morbidity in countries where unsafe abortion is common... For comments on the site, e-mail misoprostol@aon.at |
|
||||||||||||
|
Recommended misoprostol dosages (from Weeks, A. and Faundes A. Misoprostol in obstetrics and gynecology. Int J Gynaecol Obstet, 2007. 99 Suppl 2: p. S156-9.) See here for a printable pdf format of this table.
|
|||||||||||||
